In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk

Catherine Rowan

doi:10.7326/J23-0069

In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk

Ann Intern Med. 2023 Sep;176(9):JC103. doi: 10.7326/J23-0069. Epub 2023 Sep 5.

Author

Catherine Rowan¹

Affiliation

¹ University of Calgary, Calgary, Alberta, Canada (C.R.).

PMID: 37665995
DOI: 10.7326/J23-0069

Abstract

Loftus EV Jr, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388:1966-1980. 37224198.

Publication types

Comment

MeSH terms

Crohn Disease* / drug therapy
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans

Substances

upadacitinib
Heterocyclic Compounds, 3-Ring